# Investigating the causal relationship of lipid metabolism in polycystic ovary syndrome: a Mendelian randomization study on the regulatory role of 3-Hydroxybutyrate in gene expression

**Authors:** Jia Xu, Lan Li, Shuo Yang, Ping Li, Bing He, Ji-lin Kuang

PMC · DOI: 10.3389/fmed.2026.1747593 · Frontiers in Medicine · 2026-02-04

## TL;DR

This study finds that lipid metabolism and a ketone body called 3-hydroxybutyrate play a causal role in the development of polycystic ovary syndrome.

## Contribution

The study identifies a novel molecular mechanism involving 3-hydroxybutyrate and HDAC3 in the pathogenesis of PCOS.

## Key findings

- Lipid-related metabolites have a causal effect on PCOS susceptibility.
- 3-hydroxybutyrate modulates PCOS development by affecting HDAC3 activity.
- Targeting the 3-HB/HDAC3 pathway could offer new therapeutic strategies for PCOS.

## Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting 5–18% of reproductive-aged women, characterized by menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology. Beyond its endocrine manifestations, PCOS involves significant metabolic dysfunction, particularly in lipid homeostasis. Elevated triglyceride levels are closely linked to insulin resistance and cardiovascular risk, suggesting a central role for lipid dysregulation in PCOS pathogenesis. However, traditional observational studies struggle to establish causal relationships due to confounding factors and reverse causality.

To address these limitations, this study employed a two-sample Mendelian randomization (MR) design to assess the causal effects of lipid-related metabolites—specifically triglyceride-rich lipoprotein subclasses—on PCOS susceptibility. Furthermore, to elucidate potential biological mechanisms, we integrated the MR analysis with in vitro functional experiments, focusing on the role of ketone body metabolism and specifically 3-hydroxybutyrate (3-HB), a major circulating ketone body known to regulate gene expression via epigenetic modifications.

Our analysis identified a causal contribution of lipid-related metabolites to PCOS. notably, we demonstrated that 3-HB plays a critical role in the development of PCOS. Mechanistic investigations revealed that 3-HB contributes to metabolic and hormonal dysregulation primarily through the modulation of HDAC3 activity, linking ketone body metabolism directly to the disease phenotype.

This study provides robust causal evidence linking lipid metabolism and ketone bodies to PCOS, moving beyond descriptive associations. by uncovering the specific pathway involving 3-HB and HDAC3, we highlight a novel molecular mechanism underlying PCOS pathogenesis. These findings suggest that targeting the 3-HB/HDAC3 axis could offer new strategies for therapeutic intervention in managing PCOS-related metabolic dysfunction.

## Linked entities

- **Proteins:** HDAC3 (histone deacetylase 3)
- **Chemicals:** 3-hydroxybutyrate (PubChem CID 92135)
- **Diseases:** polycystic ovary syndrome (MONDO:0008487)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CYP17A1 (cytochrome P450 family 17 subfamily A member 1) [NCBI Gene 1586] {aka CPT7, CYP17, P450C17, S17AH}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, CYP11A1 (cytochrome P450 family 11 subfamily A member 1) [NCBI Gene 1583] {aka CYP11A, CYPXIA1, P450SCC}, HDAC3 (histone deacetylase 3) [NCBI Gene 8841] {aka HD3, KDAC3, RPD3, RPD3-2}, HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) [NCBI Gene 345275] {aka FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3}, LHCGR (luteinizing hormone/choriogonadotropin receptor) [NCBI Gene 3973] {aka HHG, LCGR, LGR2, LH/CG-R, LH/CGR, LHR}, STAR (steroidogenic acute regulatory protein) [NCBI Gene 6770] {aka STARD1}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2) [NCBI Gene 3284] {aka HSD3B, HSDB, SDR11E2}, FSHR (follicle stimulating hormone receptor) [NCBI Gene 2492] {aka FSHR1, FSHRO, LGR1, ODG1}
- **Diseases:** hirsutism (MESH:D006628), metabolic dysregulation (MESH:D021081), metabolic abnormalities (MESH:D008659), reproductive dysfunction (MESH:D060737), obesity (MESH:D009765), MR (MESH:C562757), Cytotoxicity (MESH:D064420), insulin resistance (MESH:D007333), cardiovascular diseases (MESH:D002318), endocrine disorder (MESH:D004700), PCOS (MESH:D011085), Lipid metabolism (MESH:D052439), hyperandrogenism (MESH:D017588), acne (MESH:D000152), ovarian dysfunction (MESH:D010049), estrogen deficiency (MESH:D056828)
- **Chemicals:** triglyceride (MESH:D014280), ketone (MESH:D007659), streptomycin (MESH:D013307), Estradiol (MESH:D004958), 3-HB (MESH:D020155), T (MESH:D014316), ketone bodies (MESH:D007657), cholesterol (MESH:D002784), Testosterone (MESH:D013739), CCK8 (MESH:D012844), RGFP966 (MESH:C000603861), penicillin (MESH:D010406), DMEM (-), glucose (MESH:D005947), lipid (MESH:D008055), CO2 (MESH:D002245), steroid hormone (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** KGN — Homo sapiens (Human), Ovarian granulosa cell tumor, Cancer cell line (CVCL_0375)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913541/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913541/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913541/full.md

---
Source: https://tomesphere.com/paper/PMC12913541